Upfront treatment with the first and second-generation tyrosine kinase inhibitors in Ph-positive acute lymphoblastic leukemia.

about

Upfront treatment with the first and second-generation tyrosine kinase inhibitors in Ph-positive acute lymphoblastic leukemia.

Item

http://www.wikidata.org/entity/Q47104794

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Upfront treatment with the fir ...... acute lymphoblastic leukemia.

@en

Upfront treatment with the fir ...... acute lymphoblastic leukemia.

@nl

type

Item

label

Upfront treatment with the fir ...... acute lymphoblastic leukemia.

@en

Upfront treatment with the fir ...... acute lymphoblastic leukemia.

@nl

prefLabel

Upfront treatment with the fir ...... acute lymphoblastic leukemia.

@en

Upfront treatment with the fir ...... acute lymphoblastic leukemia.

@nl

P1476

Upfront treatment with the fir ...... acute lymphoblastic leukemia.

@en

P2093

Changxin Yin

http://www.w3.org/2001/XMLSchema#string

Dan Xu

http://www.w3.org/2001/XMLSchema#string

Fang Chen

http://www.w3.org/2001/XMLSchema#string

Guopan Yu

http://www.w3.org/2001/XMLSchema#string

Jing Sun

http://www.w3.org/2001/XMLSchema#string

Li Xuan

http://www.w3.org/2001/XMLSchema#string

Qiang Wang

http://www.w3.org/2001/XMLSchema#string

Qianli Jiang

http://www.w3.org/2001/XMLSchema#string

Qifa Liu

http://www.w3.org/2001/XMLSchema#string

Xiaoli Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.

Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.

Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis

Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia.

P304

107022-107032

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.22206

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29291008

http://www.w3.org/2001/XMLSchema#string

P932

5739793

http://www.w3.org/2001/XMLSchema#string